H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price target Alto is redefining neuropsychiatric drug development through the application of precision medicine in psychiatry, a “paradigm-shifting approach” that targets biomarker-defined patient populations, the analyst tells investors in a research note. The firm believes the company’s “differentiated” Precision Psychiatry Platform has the potential to optimize patient-treatment matching and outcomes in central nervous system disorders.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Buy Rating Reaffirmed for Alto Neuroscience, Inc. Amid Promising Pipeline and Upcoming Data Readouts
- Promising Clinical Trials and Strong Financials Justify Buy Rating for Alto Neuroscience, Inc.
- Alto Neuroscience Advances Clinical Trials with Strong Financials
- Alto Neuroscience Announces Board Member Departures
- Alto Neuroscience, Inc. (ANRO) Q4 Earnings Cheat Sheet
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue